JPMorgan Chase & Co. initiated coverage on shares of Phreesia (NYSE:PHR) in a report released on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $33.00 price target on the stock.

Several other research analysts also recently weighed in on PHR. Wells Fargo & Co started coverage on shares of Phreesia in a research report on Monday, August 12th. They issued an outperform rating and a $23.00 target price on the stock. Chardan Capital started coverage on shares of Phreesia in a research report on Tuesday, July 23rd. They issued a buy rating and a $33.00 target price on the stock. Piper Jaffray Companies started coverage on shares of Phreesia in a research report on Monday, August 12th. They issued an overweight rating and a $33.00 target price on the stock. Finally, William Blair started coverage on shares of Phreesia in a research report on Monday, August 12th. They issued an outperform rating on the stock. Five analysts have rated the stock with a buy rating, Phreesia has a consensus rating of Buy and an average target price of $30.50.

Phreesia stock opened at $26.67 on Tuesday. Phreesia has a fifty-two week low of $23.00 and a fifty-two week high of $29.38.

In other news, major shareholder Ii L.P. Chv sold 335,767 shares of Phreesia stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $18.00, for a total value of $6,043,806.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Scott Perricelli sold 743,388 shares of Phreesia stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total transaction of $13,380,984.00. The disclosure for this sale can be found here.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

See Also: Support Level

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.